Latest Insider Transactions at Bristol Myers Squibb CO (BMY)
This section provides a real-time view of insider transactions for Bristol Myers Squibb CO (BMY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BRISTOL MYERS SQUIBB CO to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BRISTOL MYERS SQUIBB CO's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2023
|
David V Elkins EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,792
+4.85%
|
-
|
|
Dec 02
2023
|
Robert M Plenge EVP, Chief Research Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
274
-3.81%
|
$13,700
$50.1 P/Share
|
|
Dec 02
2023
|
Robert M Plenge EVP, Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
616
+7.88%
|
-
|
|
Nov 28
2023
|
Christopher S. Boerner Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
3,071
+3.72%
|
$147,408
$48.86 P/Share
|
|
Nov 21
2023
|
Sandra Leung EVP, General Counsel |
BUY
Other acquisition or disposition
|
Indirect |
9,830
+9.52%
|
$471,840
$48.74 P/Share
|
|
Nov 21
2023
|
Sandra Leung EVP, General Counsel |
SELL
Other acquisition or disposition
|
Direct |
9,830
-2.88%
|
$471,840
$48.74 P/Share
|
|
Nov 20
2023
|
Theodore R. Samuels Ii Director |
BUY
Open market or private purchase
|
Direct |
8,500
+19.32%
|
$416,500
$49.81 P/Share
|
|
Oct 10
2023
|
Giovanni Caforio Executive Chair of the Board |
SELL
Bona fide gift
|
Direct |
440
-0.12%
|
-
|
|
Aug 24
2023
|
Ann Powell EVP, Chief Human Resources |
SELL
Open market or private sale
|
Direct |
17,986
-39.22%
|
$1,097,146
$61.25 P/Share
|
|
Aug 03
2023
|
Robert M Plenge EVP, Chief Research Officer |
SELL
Open market or private sale
|
Direct |
732
-10.01%
|
$44,652
$61.14 P/Share
|
|
Jul 01
2023
|
Michelle Weese EVP, Corporate Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
682
-16.49%
|
$42,966
$63.95 P/Share
|
|
Jul 01
2023
|
Michelle Weese EVP, Corporate Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
1,885
+31.31%
|
-
|
|
Jul 01
2023
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
4,787
-9.2%
|
$301,581
$63.95 P/Share
|
|
Jul 01
2023
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
9,357
+15.24%
|
-
|
|
Jun 03
2023
|
Adam Lenkowsky EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
551
-51.16%
|
$35,815
$65.66 P/Share
|
|
Jun 03
2023
|
Adam Lenkowsky EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,077
+50.0%
|
-
|
|
May 03
2023
|
Rupert Vessey EVP & President, Research |
SELL
Open market or private sale
|
Direct |
50,385
-51.34%
|
$3,375,795
$67.06 P/Share
|
|
May 02
2023
|
Sharon Greenlees SVP & Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
346
-26.28%
|
$23,528
$68.1 P/Share
|
|
May 02
2023
|
Sharon Greenlees SVP & Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
1,017
+40.53%
|
-
|
|
May 02
2023
|
Sharon Greenlees SVP & Controller |
SELL
Other acquisition or disposition
|
Direct |
62
-9.0%
|
-
|
|
Apr 01
2023
|
Karin Shanahan EVP, Glob. Prod. Dev. & Supply |
SELL
Payment of exercise price or tax liability
|
Direct |
1,692
-34.4%
|
$116,748
$69.31 P/Share
|
|
Apr 01
2023
|
Karin Shanahan EVP, Glob. Prod. Dev. & Supply |
BUY
Exercise of conversion of derivative security
|
Direct |
3,306
+40.2%
|
-
|
|
Apr 01
2023
|
Elizabeth Mily EVP, Strategy & BD |
SELL
Payment of exercise price or tax liability
|
Direct |
3,198
-4.51%
|
$220,662
$69.31 P/Share
|
|
Apr 01
2023
|
Elizabeth Mily EVP, Strategy & BD |
BUY
Exercise of conversion of derivative security
|
Direct |
6,346
+8.33%
|
-
|
|
Apr 01
2023
|
Elizabeth Mily EVP, Strategy & BD |
BUY
Other acquisition or disposition
|
Direct |
1,190
+3.27%
|
-
|
|
Mar 10
2023
|
Elizabeth Mily EVP, Strategy & BD |
SELL
Payment of exercise price or tax liability
|
Direct |
14,040
-15.65%
|
$912,600
$65.71 P/Share
|
|
Mar 10
2023
|
Elizabeth Mily EVP, Strategy & BD |
BUY
Other acquisition or disposition
|
Direct |
3,458
+3.59%
|
-
|
|
Mar 10
2023
|
Elizabeth Mily EVP, Strategy & BD |
BUY
Exercise of conversion of derivative security
|
Direct |
29,636
+24.79%
|
-
|
|
Mar 10
2023
|
Rupert Vessey EVP & President, Research |
SELL
Payment of exercise price or tax liability
|
Direct |
38,498
-9.55%
|
$2,502,370
$65.71 P/Share
|
|
Mar 10
2023
|
Rupert Vessey EVP & President, Research |
BUY
Other acquisition or disposition
|
Direct |
8,326
+2.03%
|
-
|
|
Mar 10
2023
|
Rupert Vessey EVP & President, Research |
BUY
Exercise of conversion of derivative security
|
Direct |
66,935
+13.8%
|
-
|
|
Mar 10
2023
|
Sandra Leung EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
34,104
-1.99%
|
$2,216,760
$65.71 P/Share
|
|
Mar 10
2023
|
Sandra Leung EVP, General Counsel |
BUY
Other acquisition or disposition
|
Direct |
8,731
+0.51%
|
-
|
|
Mar 10
2023
|
Sandra Leung EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
57,990
+3.2%
|
-
|
|
Mar 10
2023
|
Ann Powell EVP, Chief Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
16,810
-8.11%
|
$1,092,650
$65.71 P/Share
|
|
Mar 10
2023
|
Ann Powell EVP, Chief Human Resources |
BUY
Other acquisition or disposition
|
Direct |
5,174
+2.61%
|
-
|
|
Mar 10
2023
|
Ann Powell EVP, Chief Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
34,447
+13.86%
|
-
|
|
Mar 10
2023
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
SELL
Payment of exercise price or tax liability
|
Direct |
22,395
-13.21%
|
$1,455,675
$65.71 P/Share
|
|
Mar 10
2023
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
BUY
Other acquisition or disposition
|
Direct |
4,800
+2.78%
|
-
|
|
Mar 10
2023
|
Samit Hirawat EVP,Chief Med.Offr.,Drug Dev. |
BUY
Exercise of conversion of derivative security
|
Direct |
38,978
+18.42%
|
-
|
|
Mar 10
2023
|
Karin Shanahan EVP, Glob. Prod. Dev. & Supply |
SELL
Payment of exercise price or tax liability
|
Direct |
914
-36.18%
|
$59,410
$65.71 P/Share
|
|
Mar 10
2023
|
Karin Shanahan EVP, Glob. Prod. Dev. & Supply |
BUY
Other acquisition or disposition
|
Direct |
79
+3.03%
|
-
|
|
Mar 10
2023
|
Karin Shanahan EVP, Glob. Prod. Dev. & Supply |
BUY
Exercise of conversion of derivative security
|
Direct |
2,447
+50.0%
|
-
|
|
Mar 10
2023
|
Giovanni Caforio Executive Chair of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
137,989
-7.63%
|
$8,969,285
$65.71 P/Share
|
|
Mar 10
2023
|
Giovanni Caforio Executive Chair of the Board |
BUY
Other acquisition or disposition
|
Direct |
35,144
+2.0%
|
-
|
|
Mar 10
2023
|
Giovanni Caforio Executive Chair of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
234,676
+11.1%
|
-
|
|
Mar 10
2023
|
David V Elkins EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
41,331
-6.11%
|
$2,686,515
$65.71 P/Share
|
|
Mar 10
2023
|
David V Elkins EVP, Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
8,930
+1.3%
|
-
|
|
Mar 10
2023
|
David V Elkins EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
71,871
+9.26%
|
-
|
|
Mar 10
2023
|
Christopher S. Boerner Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
34,620
-9.46%
|
$2,250,300
$65.71 P/Share
|